| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000010693 |
| Receipt No. | R000011383 |
| Official scientific title of the study | Investigation for the effects of hydrogen rich water on chronic hepatitis and liver cirrhosis |
| Date of disclosure of the study information | 2013/05/20 |
| Last modified on | 2017/05/14 (Ver. 3) |
| Basic information | ||
| Official scientific title of the study | Investigation for the effects of hydrogen rich water on chronic hepatitis and liver cirrhosis | |
| Title of the study (Brief title) | Hydrogen rich water for chronic hepatitis | |
| Region |
|
|
| Condition | ||
| Condition | Chronic hepatitis and liver cirrhosis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate whether hydrogen rich water reduces oxidative stress and elevated ALT levels. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Reduction of high ALT |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Cross-over |
| Randomization | Randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | No treatment |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | GroupA:drink hydrogen rich water 1L/day for 1month, following 1month washout and drink control water 1L/day for 1month. | |
| Interventions/Control_2 | GroupB:drink control water 1L/day for 1month, following 1 month washout and drink hydrogen rich water 1L/day for a month. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1)chronic hepatitis or liver cirrhosis diagnosed with liver biopsy or radiography and show ALT elevation with standard therapy.
2)Patients whose ALT levels kept beyond upper limit of normal range for more than 2 months. |
|||
| Key exclusion criteria | 1)Patients who need albumin administration more than once /week for 1 month or more.
2)Patients with edema or ascite. 3)Patients with hepatic encephalopathy. 4)Bilirubin levels equal or >2mg/dl. 5)Albumin levels <3g/dl. 6)Serum Na <130 mEq/L 7)Alcohol abuser. 8)Creatinin equal or >1.3mg/dl. 9)Patients who are receiving interferon treatment. 10)Family Doctors comment |
|||
| Target sample size | 20 | |||
| Research contact person | |
| Name of lead principal investigator | Akinobu Takaki |
| Organization | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 2-5-1Shikata Cho, Kita-Ku, Okayama City, 700-8558Japan |
| TEL | 086-235-7219 |
| akitaka@md.okayama-u.ac.jp | |
| Public contact | |
| Name of contact person | Akinobu Takaki |
| Organization | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences. |
| Division name | Department of Gastroenterology and Hepatology |
| Address | 2-5-1Shikata Cho, Kita-Ku,Okayama City |
| TEL | 086-235-7219 |
| Homepage URL | |
| akitaka@md.okayama-u.ac.jp | |
| Sponsor | |
| Institute | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences.Department of Gastroenterology and Hepatology |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences.Department of Gastroenterology and Hepatology |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000011383 |